Literature DB >> 21437769

Small interfering RNA targeting HIF-1α reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro.

Adrian Staab1, Markus Fleischer, Juergen Loeffler, Harun M Said, Astrid Katzer, Christian Plathow, Herrmann Einsele, Michael Flentje, Dirk Vordermark.   

Abstract

BACKGROUND: Hypoxia inducible factor-1 has been identified as a potential target to overcome hypoxia-induced radioresistance The aim of the present study was to investigate whether selective HIF-1 inhibition via small interfering RNA (siRNA) targeting hypoxia-inducible factor 1α (HIF-1α) affects hypoxia-induced radioresistance in HT 1080 human fibrosarcoma cells.
MATERIAL AND METHODS: HIF-1α expression in HT 1080 human fibrosarcoma cells in vitro was silenced using HIF-1α siRNA sequence primers. Quantitative real-time polymerase chain reaction assay was performed to quantify the mRNA expression of HIF-1α. HIF-1α protein levels were studied by Western blotting at 20% (air) or after 12 hours at 0.1% O2 (hypoxia). Cells were assayed for clonogenic survival after irradiation with 2, 5, or 10 Gy, under normoxic or hypoxic conditions in the presence of HIF-1α-targeted or control siRNA sequences. A modified oxygen enhancement ratio (OER´) was calculated as the ratio of the doses to achieve the same survival at 0.1% O(2) as at ambient oxygen tensions. OER´ was obtained at cell survival levels of 50%, 37%, and 10%.
RESULTS: HIF-1α-targeted siRNA enhanced radiation treatment efficacy under severely hypoxic conditions compared to tumor cells treated with scrambled control siRNA. OER was reduced on all survival levels after treatment with HIF-1α-targeted siRNA, suggesting that inhibition of HIF-1 activation by using HIF-1α-targeted siRNA increases radiosensitivity of hypoxic tumor cells in vitro.
CONCLUSION: Inhibition of HIF-1 activation by using HIF-1α-targeted siRNA clearly acts synergistically with radiotherapy and increase radiosensitivity of hypoxic cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437769     DOI: 10.1007/s00066-011-2167-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  38 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

2.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

3.  Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.

Authors:  Maria Wolf; Franz Zehentmayr; Maximilian Niyazi; Ute Ganswindt; Wolfgang Haimerl; Michael Schmidt; Dieter Hölzel; Claus Belka
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

4.  Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.

Authors:  Mario Balducci; Giuseppina Apicella; Stefania Manfrida; Annunziato Mangiola; Alba Fiorentino; Luigi Azario; Giuseppe Roberto D'Agostino; Vincenzo Frascino; Nicola Dinapoli; Giovanna Mantini; Alessio Albanese; Pasquale de Bonis; Silvia Chiesa; Vincenzo Valentini; Carmelo Anile; Numa Cellini
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

5.  Three-gene prognostic classifier for early-stage non small-cell lung cancer.

Authors:  Suzanne K Lau; Paul C Boutros; Melania Pintilie; Fiona H Blackhall; Chang-Qi Zhu; Dan Strumpf; Michael R Johnston; Gail Darling; Shaf Keshavjee; Thomas K Waddell; Ni Liu; Davina Lau; Linda Z Penn; Frances A Shepherd; Igor Jurisica; Sandy D Der; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

6.  Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.

Authors:  Kathrin Dellas; Matthias Bache; Steffi U Pigorsch; Helge Taubert; Matthias Kappler; Daniel Holzapfel; Ester Zorn; Hans-Juergen Holzhausen; Gabriele Haensgen
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

Review 7.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

8.  Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas.

Authors:  E A Griffiths; S A Pritchard; H R Valentine; N Whitchelo; P W Bishop; M P Ebert; P M Price; I M Welch; C M L West
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

Review 9.  Cellular signaling and potential new treatment targets in diabetic retinopathy.

Authors:  Zia A Khan; Subrata Chakrabarti
Journal:  Exp Diabetes Res       Date:  2007

10.  The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line.

Authors:  Lily Yang; Won-Kyung Kang
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

View more
  23 in total

1.  Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro.

Authors:  Feray Kockar; Hatice Yildrim; Rahsan Ilikci Sagkan; Carsten Hagemann; Yasemin Soysal; Jelena Anacker; Ahmed Ayad Hamza; Dirk Vordermark; Michael Flentje; Harun M Said
Journal:  World J Clin Oncol       Date:  2012-06-10

2.  Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo.

Authors:  Xi Yang; Baixia Yang; Jing Cai; Chi Zhang; Qu Zhang; Liping Xu; Qin Qin; Hongcheng Zhu; Jianxin Ma; Guangzhou Tao; Hongyan Cheng; Xinchen Sun
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

3.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

4.  Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.

Authors:  L Stingl; N Niewidok; N Müller; M Selle; C S Djuzenova; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-03-24       Impact factor: 3.621

5.  Prognostic value of HIF-1α expression during fractionated irradiation.

Authors:  L Helbig; A Yaromina; S N Sriramareddy; S Böke; L Koi; H D Thames; M Baumann; D Zips
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

6.  HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis.

Authors:  Dan Liang; Maowei Yang; Baolei Guo; Lei Yang; Junjun Cao; Xiuli Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-27       Impact factor: 4.553

7.  Effects of three modifiers of glycolysis on ATP, lactate, hypoxia, and growth in human tumor cell lines in vivo.

Authors:  A Yaromina; S Meyer; C Fabian; K Zaleska; U G A Sattler; L A Kunz-Schughart; W Mueller-Klieser; D Zips; M Baumann
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

8.  Influence of osteopontin silencing on survival and migration of lung cancer cells.

Authors:  B Polat; G Wohlleben; A Katzer; C S Djuzenova; A Technau; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

9.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

10.  STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma.

Authors:  Qu Zhang; Chi Zhang; Jia He; Qing Guo; Desheng Hu; Xi Yang; Jinfeng Wang; Yahui Kang; Ruifang She; Zhongming Wang; Defan Li; Guanhong Huang; Zhaoming Ma; Weidong Mao; Xiaoyi Zhou; Chuangying Xiao; Xinchen Sun; Jianxin Ma
Journal:  Tumour Biol       Date:  2014-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.